Literature DB >> 33585092

Atypical Neuroleptic Malignant Syndrome in the Setting of Quetiapine Overdose: A Case Report and Review of the Literature.

Sheila D Hernandez1, Dario A Marotta2,3, Ravitej Goteti1.   

Abstract

Neuroleptic malignant syndrome (NMS) is a rare and life-threatening emergency. The condition is largely iatrogenic and is often precipitated by medications such as antipsychotics. First-generation antipsychotics are more likely to cause NMS than second-generation antipsychotics. The literature lacks an objective measure for NMS diagnosis. Instead, the diagnosis relies largely on the recognition of characteristic symptoms in the presence of an inciting medication. Additional challenges exist with concomitant disease processes and toxicities that may distort the clinical picture. Here, we report a case of a 44-year-old Caucasian man who presented with atypical NMS in the setting of quetiapine overdose. The patient remained uncharacteristically afebrile throughout his admission. Although the patient recovered, extended delays in identification and management can contribute to an increased risk of morbidity and mortality.
Copyright © 2021, Hernandez et al.

Entities:  

Keywords:  atypical antipsychotic; neuroleptic malignant syndrome; overdose

Year:  2021        PMID: 33585092      PMCID: PMC7872006          DOI: 10.7759/cureus.12602

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


  19 in total

Review 1.  Neuroleptic malignant syndrome.

Authors:  P Adnet; P Lestavel; R Krivosic-Horber
Journal:  Br J Anaesth       Date:  2000-07       Impact factor: 9.166

2.  Off-label Use of Quetiapine in Medical Inpatients and Postdischarge.

Authors:  Todd C Lee; Ploa Desforges; Jennifer Murray; Ramy R Saleh; Emily G McDonald
Journal:  JAMA Intern Med       Date:  2016-09-01       Impact factor: 21.873

3.  [CD antigens and the differentiation of human lymphocytes].

Authors:  T Kuritani; S Negoro; S Kishimoto
Journal:  Hum Cell       Date:  1988-09       Impact factor: 4.174

4.  Neuroleptic malignant syndrome: long-term follow-up of 20 cases.

Authors:  H G Pope; H G Aizley; P E Keck; S L McElroy
Journal:  J Clin Psychiatry       Date:  1991-05       Impact factor: 4.384

Review 5.  Atypical neuroleptic malignant syndrome or serotonin toxicity associated with atypical antipsychotics?

Authors:  Yuji Odagaki
Journal:  Curr Drug Saf       Date:  2009-01

6.  Neuroleptic malignant syndrome: a pathogenetic role for dopamine receptor blockade?

Authors:  V W Henderson; G F Wooten
Journal:  Neurology       Date:  1981-02       Impact factor: 9.910

Review 7.  Neuroleptic malignant syndrome.

Authors:  S N Caroff; S C Mann
Journal:  Med Clin North Am       Date:  1993-01       Impact factor: 5.456

8.  Neuroleptic malignant syndrome: a review for neurohospitalists.

Authors:  Brian D Berman
Journal:  Neurohospitalist       Date:  2011-01

Review 9.  Second-generation antipsychotics and neuroleptic malignant syndrome: systematic review and case report analysis.

Authors:  Martino Belvederi Murri; Argentina Guaglianone; Michele Bugliani; Pietro Calcagno; Matteo Respino; Gianluca Serafini; Marco Innamorati; Maurizio Pompili; Mario Amore
Journal:  Drugs R D       Date:  2015-03

10.  Neuroleptic malignant syndrome: A diagnostic challenge.

Authors:  Reshma P Ambulkar; Vijaya P Patil; Aliasgar V Moiyadi
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2012-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.